Dr. Gregory Riely, MD – New York, NY

Overview of Dr. Riely

Dr. Gregory Riely is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan-Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Case Western Reserve University School of Medicine and has been in practice 16 years. Dr. Riely accepts several types of health insurance, listed below. He is one of 468 doctors at Memorial Sloan-Kettering Cancer Center and one of 82 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

• Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006

• New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2001 - 2003

• Case Western Reserve University School of MedicineClass of 2001

Certifications & Licensure

• FL State Medical License 2021 - Present

• NJ State Medical License 2022 - 2025

• NY State Medical License 2003 - 2024

• NC State Medical License 2020 - 2022

• American Board of Internal Medicine Internal Medicine
• American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

• Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry.

  Sanz-Garcia, E., Brown, S., Lavery, J., Weiss, J., Fuchs, H., Newcomb, A., Postle, A., Warner, J., LeNoue-Newton, M., Sweeney, S., Pillai, S., Yu, C., Nichols, C., Mas...> ;Cancer Research Communications. 2024 Feb 20

• A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.

  Riely, G., Smit, E., Ahn, M., Felip, E., Ramalingam, S., Tsao, A., Johnson, M., Gelsomino, F., Esper, R., Nadal, E., Offin, M., Provencio, M., Clarke, J., Hussein, M.,...> ;Future Oncology. 2024 Feb 15

• Intracranial Outcomes of De Novo Brain Metastases Treated With Osimertinib Alone in Patients With Newly Diagnosed EGFR-Mutant NSCLC.

  Reiner, A., Ilica, A., Miao, E., Panageas, K., Imber, B., Sehgal, R., Saganty, R., Li, B., Riely, G., Yu, H., Young, R., Pike, L., Moss, N.> ;JTO Clinical and Research Reports. 2023 Dec 1
• Join now to see all

Journal Articles

• Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients with Metastatic EGFR-Mutant Lung Cancers  

  Helena A Yu, Adam J Schoenfeld, Jamie E Chaft, Gregory J Riely, JAMA Oncology

• PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET Exon 14 Altered Lung Cancers  

  G J Riely, J Dienstag, C Mrad, J K Sabari, M G Kris, K C Arbour, D F Halpenny, N Rekhtman, R Chen, A J Plodkowski, P K Paik, B T Li, I Bergagnini, M D Offin, C M Rudin..., Annals of Oncology

• YES1 Amplification Is a Mechanism of Acquired Resistance to EGFR Inhibitors Identified by Transposon Mutagenesis and Clinical Genomics  

  Emmet J Jordan, Helena A Yu, Yelena Y Janjigian, Mark G Kris, Paul K Paik, Jamie E Chaft, Lu Wang, Gregory J Riely, Proceedings of the National Academy of Sciences

Lectures

• Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC. 

  2019 ASCO Annual Meeting - 6/1/2019

• American Society for Radiation Oncology(ASTRO): 20th Chicago Multidisciplinary Symposium inThoracic Oncology 

  American Society for Radiation Oncology, Chicago, Illinois - 9/6/2012

• Treating Stage I to III Non-Small-Cell Lung Cancer With Limited Evidence 

  2013 International Conference, Philadelphia, Pennsylvania, USA
• Join now to see all

Press Mentions

• Second Drug Targeting KRASG12C Shows Benefit in Mutated Non-Small-Cell Lung CancerMarch 25th, 2021

• Lung Cancer | Current Concepts and Recent Advances in Oncology Part 1: Lung CancerDecember 30th, 2020

• Two New Targeted Therapies Appear Encouraging for Difficult Drivers in NSCLCJune 4th, 2019

• Join now to see all

Hospital Affiliations

Insurance Accepted

• Aetna Choice POS II
  Aetna HMO
  BCBS Blue Card PPO
  CIGNA HMO
  CIGNA Open Access
  CIGNA PPO
  Empire BCBS HMO
  Empire BCBS PPO
  Great West PPO
  Humana ChoiceCare Network PPO
  

  Kaiser Permanente
  Multiplan PHCS PPO
  Multiplan PPO
  MVP Healthcare PPO
  Oxford Health Freedom
  Oxford Health Liberty
  QualCare HMO
  QualCare PPO
  United Healthcare - Direct Choice Plus POS
  United Healthcare - Direct Options PPO
  

• Please verify your coverage with the provider's office directly when scheduling an appointment